2.2.0.25falsefalse0202 - Disclosure - Significant Accounting Policiestruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0001113481duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0mdco_SignificantAccountingPoliciesAbstractmdcofalsenadurationSignificant Accounting Policies.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringSignificant Accounting Policies.falsefalse3false0us-gaap_SignificantAccountingPoliciesTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 2 - us-gaap:SignificantAccountingPoliciesTextBlock-->
<div align="left" style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent; text-align: left">
<tr>
<td width="3%"></td>
<td width="97%"></td>
</tr>
<tr valign="top">
<td>
<b><font style="font-family: 'Times New Roman', Times">2.  </font></b>
</td>
<td>
<b><font style="font-family: 'Times New Roman', Times">Significant
Accounting Policies</font></b>
</td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Basis
of Presentation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The consolidated financial statements include the accounts of
the Company and its wholly owned subsidiaries. All significant
intercompany balances and transactions have been eliminated in
consolidation. The Company has no unconsolidated subsidiaries or
investments accounted for under the equity method.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Use of
Estimates</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that
affect the reported amounts of assets, liabilities, revenue,
costs, expenses and accumulated other comprehensive
income/(loss) that are reported in the consolidated financial
statements and accompanying disclosures. Actual results may be
different.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Reclassifications</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Certain prior year amounts have been reclassified to conform to
the current year presentation.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Risks
and Uncertainties</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company is subject to risks common to companies in the
pharmaceutical industry including, but not limited to,
uncertainties related to commercialization of products,
regulatory approvals, dependence on key products, dependence on
key customers and suppliers, and protection of intellectual
property rights.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Concentrations
of Credit Risk</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Financial instruments that potentially subject the Company to
concentration of credit risk include cash, cash equivalents,
available for sale securities and accounts receivable. The
Company believes it minimizes its exposure to potential
concentrations of credit risk by placing investments in
high-quality financial instruments with high quality
institutions. At December 31, 2010 and 2009, approximately
$12.2 million and $25.1 million, respectively, of the
Company’s cash and cash equivalents was invested in a
single fund, the Dreyfus Cash Management Money Market Fund, a
no-load money market fund with Capital Advisors Group.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
In March 2007, the Company began selling Angiomax in the United
States to a sole source distributor, Integrated
Commercialization Solutions, Inc. (ICS). The Company began
selling Cleviprex to ICS in September 2008. ICS accounted for
94%, 96% and 96% of the Company’s net revenue for 2010,
2009 and 2008, respectively. At December 31, 2010 and 2009,
amounts due from ICS represented approximately
$55.2 million and $33.8 million, or 90% and 94%, of
gross accounts receivable, respectively. At December 31,
2010 and 2009, the Company maintained an allowance for doubtful
accounts for its ICS accounts receivable of $0.1 million.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Cash,
Cash Equivalents and Available for Sale Securities</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company considers all highly liquid investments purchased
with original maturities at the date of purchase of three months
or less to be cash equivalents. Cash and cash equivalents
included cash of $114.1 million and $24.7 million at
December 31, 2010 and December 31, 2009, respectively.
Cash and cash equivalents at December 31, 2010 and
December 31, 2009 included investments of
$12.2 million and $47.5 million, respectively, in
money market funds and commercial paper with original maturities
of less than three months. These investments are carried at
cost, which approximates fair value. The Company measures all
original maturities from the date the investment was originally
purchased by the Company.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company considers securities with original maturities of
greater than three months to be available for sale securities.
Securities under this classification are recorded at fair market
value and unrealized gains and losses are recorded as a separate
component of stockholders’ equity. The estimated fair value
of the available for sale securities is determined based on
quoted market prices or rates for similar instruments. In
addition, the cost of debt securities in this category is
adjusted for amortization of premium and accretion of discount
to maturity. The Company evaluates securities with unrealized
losses to determine whether such losses are other than temporary.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company held available for sale securities with a fair value
totaling $120.3 million at December 31, 2010 and
$104.0 million at December 31, 2009. These available
for sale securities included various United States government
agency notes, corporate debt securities and asset backed
securities. At December 31, 2010, approximately
$115.2 million of available for sale securities were due
within one year. The remaining $5.1 million were due within
two years. At December 31, 2009, approximately
$100.3 million of available for sale securities were due
within one year. The remaining $3.7 million were due within
two years.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Available for sale securities, including carrying value and
estimated fair values, are summarized as follows:
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="34%"> </td><!-- colindex=01 type=maindata -->
<td width="1%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="1%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="1%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="1%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="1%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
<td width="1%"> </td><!-- colindex=07 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=07 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=07 type=body -->
<td width="1%" align="left"> </td><!-- colindex=07 type=hang1 -->
<td width="1%"> </td><!-- colindex=08 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=08 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=08 type=body -->
<td width="1%" align="left"> </td><!-- colindex=08 type=hang1 -->
<td width="1%"> </td><!-- colindex=09 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=09 type=lead -->
<td width="6%" align="right"> </td><!-- colindex=09 type=body -->
<td width="1%" align="left"> </td><!-- colindex=09 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">As of December 31,
2010</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">As of December 31,
2009</font></b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b><font style="color: #0c1c47">Carrying<br />
</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b><font style="color: #0c1c47">Unrealized<br />
</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b><font style="color: #0c1c47">Carrying<br />
</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b><font style="color: #0c1c47">Unrealized<br />
</font></b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Cost</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Fair Value</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Value</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Gain</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Cost</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Fair Value</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Value</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Gain</font></b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="30" align="center" valign="bottom">
<b><font style="color: #0c1c47">(In thousands)</font></b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
U.S. government agency notes
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55,222
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55,222
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
55,222
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
103,936
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
103,965
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
103,965
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Corporate debt securities
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
65,055
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
65,058
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
65,058
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td nowrap="nowrap" align="left" valign="bottom">
<div style="text-indent: -9pt; margin-left: 9pt">
Total
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
120,277
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
120,280
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
120,280
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
103,936
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
103,965
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
103,965
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
29
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Investments</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company accounts for its investment in a minority interest
of a company over which it does not exercise significant
influence on the cost method in accordance with the Financial
Accounting Standards Board (FASB) Accounting Standards
Codification (ASC)
<font style="white-space: nowrap">325-20,</font>
“Cost Method Investments” (ASC
<font style="white-space: nowrap">325-20).</font>
Under the cost method, an investment is carried at cost until it
is sold or there is evidence that changes in the business
environment or other facts and circumstances suggest it may be
other than temporarily impaired based on criteria outlined in
<font style="white-space: nowrap">ASC 325-20.</font>
These non-marketable securities have been classified as
investments and included in other assets on the consolidated
balance sheets.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Restricted
Cash</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company had restricted cash of $5.8 million at
December 31, 2010 and $7.0 million at
December 31, 2009, which is included in restricted cash on
the consolidated balance sheets. On October 11, 2007, the
Company entered into a lease for new office space in Parsippany,
New Jersey. The Company relocated its principal executive
offices to the new space in the first quarter of 2009.
Restricted cash of $5.5 million and $6.8 million at
December 31, 2010 and December 31, 2009, respectively,
collateralizes outstanding letters of credit associated with
this lease. The funds are invested in certificates of deposit.
The letter of credit permits draws by the landlord to cure
defaults by the Company. The amount of the letter of credit is
subject to reduction upon the achievement of certain regulatory
and operational milestones relating to the Company’s
products. However, in no event will the amount of the letter of
credit be reduced below approximately $1.0 million. In
addition, as a result of the acquisition of Targanta
Therapeutics Corporation (Targanta) in 2009, the Company had at
December 31, 2010 and December 31, 2009 restricted
cash of $0.3 million and $0.2 million, respectively,
in the form of a guaranteed investment certificate
collateralizing an available credit facility.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Revenue
Recognition</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
<i>Product Sales.</i>  The Company distributes
Angiomax in the United States through a sole source distribution
model. Under this model, the Company sells Angiomax to its sole
source distributor, ICS, which then sells Angiomax to a limited
number of national medical and pharmaceutical wholesalers with
distribution centers located throughout the United States and in
certain cases, directly to hospitals. The Company used ICS as
its distributor for Cleviprex prior to the recalls of Cleviprex
and related supply issues and plans to use ICS at such time as
it is able to resupply the market with Cleviprex and resume
sales. The Company’s agreement with ICS, which it initially
entered into February 2007, provides that ICS will be the
Company’s exclusive distributor of Angiomax and Cleviprex
in the United States. Under the terms of this
<font style="white-space: nowrap">fee-for-service</font>
agreement, ICS places orders with us for sufficient quantities
of Angiomax and Cleviprex to maintain an appropriate level of
inventory based on our customers’ historical purchase
volumes. In addition, ICS assumes all credit and inventory risks
and is subject to our standard return policy. ICS has sole
responsibility for determining the prices at which it sells
Angiomax and Cleviprex, subject to specified limitations in the
agreement. The agreement terminates on September 30, 2013,
but will automatically renew for additional one-year periods
unless either party gives notice at least 90 days prior to
the automatic extension. Either party may terminate the
agreement at any time and for any reason upon 180 days
prior written notice to the other party. In addition, either
party may terminate the agreement upon an uncured default of a
material obligation by the other party and in other specified
conditions.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Outside of the United States, the Company sells Angiomax either
directly to hospitals or to wholesalers or international
distributors, which then sell Angiomax to hospitals. The Company
had deferred revenue of $0.5 million as of
December 31, 2010 and $0.4 million as
December 31, 2009 associated with sales of Angiomax to
wholesalers outside of the United States. The Company recognizes
revenue from such sales when hospitals purchase the product from
the wholesaler.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company does not recognize revenue from product sales until
there is persuasive evidence of an arrangement, delivery has
occurred, the price is fixed and determinable, the buyer is
obligated to pay the Company, the obligation to pay is not
contingent on resale of the product, the buyer has economic
substance apart from the Company, the Company has no obligation
to bring about the sale of the product, the amount of returns
can be reasonably estimated and collectability is reasonably
assured.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company began selling Cleviprex in the United States in
September 2008. The Company does not recognize revenue upon
product shipment to ICS. Instead, upon product shipment, the
Company invoices ICS, records deferred revenue at gross invoice
sales price, classifies the cost basis of the product held by
ICS as finished goods inventory held by others and includes such
cost basis amount within prepaid expenses and other
current assets on its consolidated balance sheets. The Company
currently recognizes the deferred revenue when hospitals
purchase product and will do so until such time that it has
sufficient information to develop reasonable estimates of
expected returns and other adjustments to gross revenue. When
such estimates are developed, the Company expects to recognize
Cleviprex revenue upon shipment to ICS in the same manner as it
recognizes Angiomax revenue. During the third quarter of 2009,
the Company reduced its contract price for Cleviprex which had
the effect of reducing the deferred revenue by approximately
$4.0 million. In the fourth quarter of 2009, the Company
announced a voluntary recall of 11 lots of Cleviprex, including
any remaining unsold inventory associated with its initial
wholesaler orders, which resulted in a reduction of deferred
revenue of approximately $2.0 million. In 2009, the Company
recognized $3.0 million of Cleviprex revenue related to
purchases by hospitals. The Company recognized $0.8 million
of revenue associated with Cleviprex during 2010 related to
purchases by hospitals. The Company has not sold Cleviprex since
the first quarter of 2010.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company records allowances for chargebacks and other
discounts or accruals for product returns, rebates and
<font style="white-space: nowrap">fee-for-service</font>
charges at the time of sale, and reports revenue net of such
amounts. In determining the amounts of certain allowances and
accruals, the Company must make significant judgments and
estimates. For example, in determining these amounts, the
Company estimates hospital demand, buying patterns by hospitals
and group purchasing organizations from wholesalers and the
levels of inventory held by wholesalers and by ICS. Making these
determinations involves estimating whether trends in past
wholesaler and hospital buying patterns will predict future
product sales. The Company receives data periodically from ICS
and wholesalers on inventory levels and levels of hospital
purchases and the Company considers this data in determining the
amounts of these allowances and accruals.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The nature of the Company’s allowances and accruals
requiring critical estimates, and the specific considerations it
uses in estimating their amounts are as follows.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="text-align: left">
<tr>
<td width="4%"></td>
<td width="2%"></td>
<td width="94%"></td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
<td> </td>
<td> <i>• </i>
</td>
<td align="left">
<i>Product returns.</i>  The Company’s customers
have the right to return any unopened product during the
<font style="white-space: nowrap">18-month</font>
period beginning six months prior to the labeled expiration date
and ending 12 months after the labeled expiration date. As
a result, in calculating the accrual for product returns, the
Company must estimate the likelihood that product sold might not
be used within six months of expiration and analyze the
likelihood that such product will be returned within
12 months after expiration. The Company considers all of
these factors and adjusts the accrual periodically throughout
each quarter to reflect actual experience. When customers return
product, they are generally given credit against amounts owed.
The amount credited is charged to the Company’s product
returns accrual.
</td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 6%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
In estimating the likelihood of product being returned, the
Company relies on information from ICS and wholesalers regarding
inventory levels, measured hospital demand as reported by
third-party sources and internal sales data. The Company also
considers the past buying patterns of ICS and wholesalers, the
estimated remaining shelf life of product previously shipped,
the expiration dates of product currently being shipped, price
changes of competitive products and introductions of generic
products.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 6%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
At December 31, 2010 and December 31, 2009, the
Company’s accrual for product returns was $0.6 million
and $3.8 million, respectively. Included within the accrual
at December 31, 2009 was a reserve of $1.3 million
that the Company established related to the Cleviprex product
recall which occurred in December 2009.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="text-align: left">
<tr>
<td width="4%"></td>
<td width="2%"></td>
<td width="94%"></td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
<td> </td>
<td> <i>• </i>
</td>
<td align="left">
<i>Chargebacks and rebates.</i>  Although the Company
primarily sells products to ICS in the United States, the
Company typically enters into agreements with hospitals, either
directly or through group purchasing organizations acting on
behalf of their hospital members, in connection with the
hospitals’ purchases of products.
</td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 6%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Based on these agreements, most of the Company’s hospital
customers have the right to receive a discounted price for
products and volume-based rebates on product purchases. In the
case of discounted
pricing, the Company typically provides a credit to ICS, or a
chargeback, representing the difference between ICS’s
acquisition list price and the discounted price. In the case of
the volume-based rebates, the Company typically pays the rebate
directly to the hospitals.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 6%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
As a result of these agreements, at the time of product
shipment, the Company estimates the likelihood that product sold
to ICS might be ultimately sold to a contracting hospital or
group purchasing organization. The Company also estimates the
contracting hospital’s or group purchasing
organization’s volume of purchases.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 6%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company bases its estimates on industry data, hospital
purchases and the historic chargeback data it receives from ICS,
most of which ICS receives from wholesalers, which detail
historic buying patterns and sales mix for particular hospitals
and group purchasing organizations, and the applicable customer
chargeback rates and rebate thresholds.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 6%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company’s allowance for chargebacks was
$13.9 million and $4.7 million at December 31,
2010 and December 31, 2009, respectively. The
Company’s accrual for rebates was $0.0 million at
December 31, 2010 and 2009.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="text-align: left">
<tr>
<td width="4%"></td>
<td width="2%"></td>
<td width="94%"></td>
</tr>
<tr valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
<td> </td>
<td> <i>• </i>
</td>
<td align="left">
<i><font style="white-space: nowrap">Fees-for-service.</font></i>  The
Company offers discounts to certain wholesalers and ICS based on
contractually determined rates for certain services. The Company
estimates its
<font style="white-space: nowrap">fee-for-service</font>
accruals and allowances based on historical sales, wholesaler
and distributor inventory levels and the applicable discount
rate. The Company’s discounts are accrued at the time of
the sale and are typically settled with the wholesalers or ICS
within 60 days after the end of each respective quarter.
The Company’s
<font style="white-space: nowrap">fee-for-service</font>
accruals and allowances were $2.6 million and
$3.1 million at December 31, 2010 and
December 31, 2009, respectively.
</td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company has adjusted its allowances for chargebacks and
accruals for product returns, rebates and
<font style="white-space: nowrap">fees-for-service</font>
in the past based on actual sales experience, and the Company
will likely be required to make adjustments to these allowances
and accruals in the future. The Company continually monitors its
allowances and accruals and makes adjustments when the Company
believes actual experience may differ from its estimates. The
allowances included in the table below reflect these adjustments.
</div>
<!-- XBRL Pagebreak Begin -->
</div>
<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<div style="margin-left: 0%">
<!-- BEGIN PAGE WIDTH -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<div style="margin-top: 0pt; font-size: 1pt">
</div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b>
<font style="font-family: 'Times New Roman', Times">
</font>
</b>
</div>
<!-- XBRL Pagebreak End -->
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The following table provides a summary of activity with respect
to the Company’s sales allowances and accruals during 2010,
2009 and 2008 (amounts in thousands):
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<table border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent; text-align: left">
<!-- Table Width Row BEGIN -->
<tr style="font-size: 1pt" valign="bottom">
<td width="51%"> </td><!-- colindex=01 type=maindata -->
<td width="2%"> </td><!-- colindex=02 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=02 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=02 type=body -->
<td width="1%" align="left"> </td><!-- colindex=02 type=hang1 -->
<td width="3%"> </td><!-- colindex=03 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=03 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=03 type=body -->
<td width="1%" align="left"> </td><!-- colindex=03 type=hang1 -->
<td width="3%"> </td><!-- colindex=04 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=04 type=lead -->
<td width="7%" align="right"> </td><!-- colindex=04 type=body -->
<td width="1%" align="left"> </td><!-- colindex=04 type=hang1 -->
<td width="3%"> </td><!-- colindex=05 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=05 type=lead -->
<td width="4%" align="right"> </td><!-- colindex=05 type=body -->
<td width="1%" align="left"> </td><!-- colindex=05 type=hang1 -->
<td width="3%"> </td><!-- colindex=06 type=gutter -->
<td width="1%" align="right"> </td><!-- colindex=06 type=lead -->
<td width="5%" align="right"> </td><!-- colindex=06 type=body -->
<td width="1%" align="left"> </td><!-- colindex=06 type=hang1 -->
</tr>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b><font style="color: #0c1c47">Cash<br />
</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom">
<b><font style="color: #0c1c47">Fees-for-<br />
</font></b>
</td>
<td>
 
</td>
</tr>
<tr style="font-size: 8pt" valign="bottom" align="center">
<td nowrap="nowrap" align="center" valign="bottom">
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Discounts</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Returns</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Chargebacks</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Rebates</font></b>
</td>
<td>
 
</td>
<td>
 
</td>
<td colspan="2" nowrap="nowrap" align="center" valign="bottom" style="border-bottom: 1px solid #0c1c47">
<b><font style="color: #0c1c47">Service</font></b>
</td>
<td>
 
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td> 
</td>
</tr>
<!-- TableOutputBody -->
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Balance at January 1, 2008</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
507
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,060
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
597
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,662
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,657
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Allowances for sales during 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
7,510
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
138
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
5,628
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,413
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
6,562
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Allowances for prior year sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
159
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
123
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Allowances for sales in Nycomed territory
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Actual credits issued for prior year’s sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(506
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(261
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(720
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,397
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(721
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Actual credits issued for prior year’s sales in Nycomed
territory
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(2,121
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Actual credits issued for sales during 2008
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6,829
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(4,442
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,247
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(5,542
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Balance at December 31, 2008</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
682
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
975
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,186
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
431
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,956
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Allowances for sales during 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
8,291
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,764
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13,439
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
212
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9,582
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Allowances for prior year sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
274
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Actual credits issued for prior year’s sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(648
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,249
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,174
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(275
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(1,670
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Actual credits issued for sales during 2009
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(7,661
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(8,787
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(357
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(6,743
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Balance at December 31, 2009</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
664
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,764
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
4,664
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,125
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Allowances for sales during 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
9,817
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
3,420
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
53,756
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
10,976
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Allowances for prior year sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,163
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Actual credits issued for prior year’s sales
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(688
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3,811
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(4,041
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3,051
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="background: #cceeff">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 20pt">
Actual credits issued for sales during 2010
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(8,674
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(3,909
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(40,516
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
—
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td nowrap="nowrap" align="right" valign="bottom">
(8,416
</td>
<td nowrap="nowrap" align="left" valign="bottom">
)
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td style="border-top: 1px solid #0c1c47">
 
</td>
<td>
 
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<b>Balance at December 31, 2010</b>
</div>
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
1,119
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
627
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
13,863
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
11
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
<td>
 
</td>
<td nowrap="nowrap" align="left" valign="bottom">
$
</td>
<td nowrap="nowrap" align="right" valign="bottom">
2,634
</td>
<td nowrap="nowrap" align="left" valign="bottom">
 
</td>
</tr>
<tr valign="bottom" style="font-size: 1pt">
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
<td>
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td style="border-top: 3px double #0c1c47">
 
</td>
<td>
 
</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Included within the balance at January 1, 2008 above is the
reserve of $3.0 million that the Company recorded during
the fourth quarter of 2007 for the existing inventory at Nycomed
which the Company did not believe would be sold prior to the
termination of the transitional distribution agreement and would
be subject to purchase in accordance with the agreement. During
2008, the Company reduced the reserve by $2.2 million as
Nycomed sold a portion of the existing inventory during the
year. Such amount is included within the 2008 allowances above.
In 2009, the Company reimbursed Nycomed $0.8 million for
the final amount of inventory held by Nycomed at
December 31, 2008.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
<i>International Distributors.</i>  Under the
Company’s agreements with its primary international
distributors, the Company sells Angiomax to these distributors
at a fixed price. The established price is typically determined
once per year, prior to the first shipment of Angiomax to the
distributor each year. The minimum selling price used in
determining the price is 50% of the average net unit selling
price.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Revenue associated with sales to the Company’s
international distributors during 2010, 2009 and 2008 was
$4.5 million, $4.4 million and $6.6 million,
respectively. During 2008, the Company reduced the Nycomed
inventory reserve by $2.2 million as Nycomed sold a portion
of its existing inventory during the year. Such amounts are
included in the $6.6 million of revenue associated with
sales to the Company’s international distributors during
2008. As a result, the Company reduced its reserve for existing
inventory to $0.8 million, which resulted in an increase in
international net revenue. The Company reimbursed Nycomed
$0.8 million in July 2009 for the final amount of inventory
held by Nycomed at December 31, 2008.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
<i>Revenue from Collaborations.</i>  Under the terms
of the transitional distribution agreement with Nycomed, the
Company was entitled to receive a specified percentage of
Nycomed’s net sales of Angiox to third parties.
In the event the Angiox sold was purchased by Nycomed from the
Company prior to July 1, 2007, the amount the Company is
entitled to receive in connection with such sale was reduced by
the amount previously paid by Nycomed to the Company for such
product. Accordingly, revenue related to the transitional
distribution agreement with Nycomed entered into in 2007, under
which Nycomed provided product distribution services through the
second half of 2008, was not recognized until the product was
sold by Nycomed to a hospital customer. For the year ended
December 31, 2008, the Company recorded $3.8 million
of net revenue from sales made by Nycomed of approximately
$8.2 million under the transitional distribution agreement.
The Company recorded such amount as revenue from collaborations
and included it in net revenue on the Company’s
consolidated statements of operations. Because the Company
assumed control of the distribution of Angiox in all countries
in the former Nycomed territory by December 31, 2008, the
Company did not have any revenue from collaborations during the
year ended December 31, 2009 and 2010.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Cost
of Revenue</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Cost of revenue consists of expenses in connection with the
manufacture of Angiomax and Cleviprex sold, royalty expenses
under the Company’s agreements with Biogen Idec, Inc.
(Biogen Idec), Health Research Inc. (HRI) and AstraZeneca AB
(AstraZeneca) and the logistics costs of selling Angiomax and
Cleviprex, such as distribution, storage and handling.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Advertising
Costs</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company expenses advertising costs as incurred. Advertising
costs were approximately $1.5 million, $2.1 million
and $5.5 million for the years ended December 31,
2010, 2009, and 2008, respectively.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Inventory</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company records inventory upon the transfer of title from
the Company’s vendors. Inventory is stated at the lower of
cost or market value and valued using
<font style="white-space: nowrap">first-in,</font>
first-out methodology. Angiomax and Cleviprex bulk substance is
classified as raw materials and its costs are determined using
acquisition costs from the Company’s contract
manufacturers. The Company records
<font style="white-space: nowrap">work-in-progress</font>
costs of filling, finishing and packaging against specific
product batches. The Company obtains all of its Angiomax bulk
drug substance from Lonza Braine, S.A. Under the terms of the
Company’s agreement with Lonza Braine, the Company provides
forecasts of its annual needs for Angiomax bulk substance
18 months in advance. The Company also has a separate
agreement with Ben Venue Laboratories, Inc. for the fill-finish
of Angiomax drug product. The Company obtains all of its
Cleviprex bulk drug substance from Johnson Matthey Pharma
Services and also has a separate agreement with Hospira, Inc.
(Hospira) for the fill-finish of Cleviprex drug product.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Fixed
Assets</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Fixed assets are stated at cost. Depreciation is provided using
the straight-line method based on estimated useful lives or, in
the case of leasehold improvements, over the lesser of the
useful lives or the lease terms.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Recoverability
of Long-Lived Assets</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company reviews the carrying value of goodwill and
indefinite lived intangible assets annually and whenever
indicators of impairment are present. The Company determines
whether goodwill may be impaired by comparing the carrying value
of its reporting unit to the fair value of its reporting unit
determined using an income approach valuation. A reporting unit
is defined as an operating segment or one level below an
operating segment. Long-lived assets used in operations and
amortizing intangible assets are reviewed for impairment
whenever events or changes in circumstances indicate that
carrying amounts may not be recoverable. For long-lived assets
to be held and used, the Company recognizes an impairment loss
only if its carrying amount is not recoverable through its
undiscounted cash flows and measures the impairment loss
based on the difference between the carrying amount and the fair
value. Based on the Company’s analysis, there was no
impairment of goodwill and indefinite lived intangible assets in
connection with the annual impairment tests that were performed
during 2010.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Research
and Development</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Research and development costs are expensed as incurred.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Stock-Based
Compensation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company accounts for share-based compensation in accordance
with ASC topic
<font style="white-space: nowrap">718-10</font> (ASC
<font style="white-space: nowrap">718-10),</font> and
recognizes expense using the accelerated expense attribution
method.
<font style="white-space: nowrap">ASC 718-10</font>
requires companies to recognize compensation expense in an
amount equal to the fair value of all share-based awards granted
to employees. The Company estimates the fair value of its
options on the date of grant using the Black-Scholes closed-form
option-pricing model.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
Expected volatilities are based on historic volatility of the
Company’s common stock as well as implied volatilities of
peer companies in the life science industry over a range of
periods from 12 to 60 months and other factors. The Company
uses historical data to estimate forfeiture rate. The expected
term of options represents the period of time that options
granted are expected to be outstanding. The Company has made a
determination of expected term by analyzing employees’
historical exercise experience and has made estimates of future
exercises of unexercised options based on the midpoint between
the vesting date and end of the contractual term. The risk-free
interest rate is based on the U.S. Treasury yield in effect
at the time of grant corresponding with the expected life of the
options.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Translation
of Foreign Currencies</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The functional currencies of the Company’s foreign
subsidiaries are the local currencies: Euro, Swiss franc,
and British pound sterling. The Company’s assets and
liabilities are translated using the current exchange rate as of
the balance sheet date. Stockholders’ equity is translated
using historical rates at the balance sheet date. Expenses and
items of income are translated using a weighted average exchange
rate over the period ended on the balance sheet date.
Adjustments resulting from the translation of the financial
statements of the Company’s foreign subsidiaries into
U.S. dollars are excluded from the determination of net
earnings (loss) and are accumulated in a separate component of
stockholders’ equity. Foreign exchange transaction gains
and losses are included in the Company’s results of
operations.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Income
Taxes</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company provides for income taxes in accordance with ASC
topic 740 (ASC 740).
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
In accordance with ASC 740, the Company uses a two-step
approach for recognizing and measuring tax benefits taken or
expected to be taken in a tax return and disclosures regarding
uncertainties in income tax positions. The first step is
recognition: the Company determines whether it is more likely
than not that a tax position will be sustained upon examination,
including resolution of any related appeals or litigation
processes, based on the technical merits of the position. In
evaluating whether a tax position has met the
more-likely-than-not recognition threshold, the Company presumed
that the position will be examined by the appropriate taxing
authority that has full knowledge of all relevant information.
The second step is measurement: a tax position that meets the
more-likely-than-not recognition threshold is measured to
determine the amount of benefit to recognize in the financial
statements. The tax position is measured at the largest amount
of benefit that is greater than 50% likely of being realized
upon ultimate settlement. The recognition of this tax benefit
may impact the effective income tax rate if such tax benefit is
more likely than not to be realized when such benefit is
recognized. The Company does not anticipate a significant change
in its unrecognized tax benefits in
the next twelve months. The Company is no longer subject to
federal, state or foreign income tax audits for tax years prior
to 2006, however such taxing authorities can review any net
operating losses utilized by the Company in years subsequent to
2006.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
In accordance with ASC 740, deferred tax assets and
liabilities are determined based on differences between
financial reporting and income tax bases of assets and
liabilities, as well as net operating loss carryforwards, and
are measured using the enacted tax rates and laws in effect when
the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance to reflect the uncertainty
associated with ultimate realization.
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company recognizes potential interest and penalties relating
to income tax positions as a component of the benefit
(provision) for income taxes.
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Comprehensive
Income (Loss)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Company reports comprehensive income (loss) and its
components in accordance with the provisions of
SFAS No. 130, “Reporting Comprehensive
Income”, which was later superseded by the FASB
Codification and included in ASC topic
<font style="white-space: nowrap">220-10</font> (ASC
<font style="white-space: nowrap">220-10).</font>
Comprehensive income (loss) includes net income (loss), all
changes in equity for cumulative translations adjustments
resulting from the consolidation of foreign subsidiaries’
financial statements and unrealized gain (loss) on available for
sale securities.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringThis element may be used to describe all significant accounting policies of the reporting entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 22
-Paragraph 8
falsefalse12Significant Accounting PoliciesUnKnownUnKnownUnKnownUnKnownfalsetrue